{
    "relation": [
        [
            "",
            "Valproate",
            "Placebo"
        ],
        [
            "Description",
            "250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout",
            "Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout"
        ]
    ],
    "pageTitle": "Valproate in Dementia (VALID) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00071721?sect=X025&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988250.59/warc/CC-MAIN-20150728002308-00219-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859750518,
    "recordOffset": 859734124,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Valproate Drug: Placebo Interventions: Alzheimer Disease Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: July 6, 2010 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Valproate \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 153 \u00a0 \u00a0 160 \u00a0 COMPLETED \u00a0 \u00a0 81 \u00a0 \u00a0 69 \u00a0 NOT COMPLETED \u00a0 \u00a0 72 \u00a0 \u00a0 91 \u00a0 \u00a0 Baseline Characteristics \u00a0 Show Baseline Characteristics \u00a0 Outcome Measures \u00a0 Hide All Outcome Measures 1.\u00a0 Primary: \u00a0 Presence of",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}